Nuvalent Inc (NUVL)vsRevolution Medicines Inc (RVMD)
NUVL
Nuvalent Inc
$105.28
+2.81%
HEALTHCARE · Cap: $8.09B
RVMD
Revolution Medicines Inc
$141.81
-0.49%
HEALTHCARE · Cap: $30.30B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. NUVL earns a higher WallStSmart Score of 25/100 (F).
NUVL
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Trading at 17.1x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bear Case : NUVL
The primary concerns for NUVL are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
NUVL is growing revenue faster at 0.0% — sustainability is the question.
NUVL generates stronger free cash flow (-73M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NUVL scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company specializing in the development of targeted therapies for cancer patients with genetically defined diseases. Utilizing its proprietary drug discovery platform, Nuvalent aims to deliver innovative solutions that specifically address genetic mutations implicated in tumor growth, thereby enhancing patient outcomes while reducing side effects. With a robust pipeline of highly selective therapies, the company is strategically positioned to capitalize on emerging opportunities within the precision oncology market, emphasizing its commitment to transforming cancer treatment and significantly improving patient care in the oncology landscape.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?